Central gastric antisecretory action of XXXX in the @entity35 .

@entity19350 @entity2544 @entity859 @entity9113 @entity935 @entity18229 @entity2955 @entity14922 @entity2918 @entity1510 @entity36408 @entity1154 @entity750 @entity35 @entity3352 @entity1063 @entity5402 @entity45605
The effects of intracerebroventricularly (i.c.v.) administered @entity859 and some of its analogues on gastric secretion were studied in @entity35 . The compounds inhibited the gastric output of acid, pepsin and fluid in pylorus-ligated @entity35 in a dose-dependent manner with an order of potency: @entity19350 ( @entity19350 ) greater than @entity45605 ( @entity36408 ) greater than @entity45605 ( @entity36408 ) greater than @entity859 . Pretreatment with 10 and 30 mg/kg of @entity2544 i.v. or 5 mg/kg of @entity14922 s.c. did not modify the antisecretory effect of 0.1 microgram of @entity19350 i.c.v. @entity19350 injected i.c.v. did not affect the secretion induced by @entity5402 in awake @entity35 subjected to vagotomy or in anaesthetized @entity35 with intact vagi. @entity19350 i.c.v. had no effect on the serum concentration of @entity9113 . The depletion of brain @entity1154 ( @entity1063 , @entity935 and @entity750 ) with @entity2955 i.c.v. significantly attenuated the inhibitory action of @entity19350 . Pretreatment with 10 mg/kg of @entity1510 i.v. or @entity3352 s.c. did not modify the antisecretory effect of @entity19350 . The results indicate that @entity859 inhibits gastric secretion in @entity35 by a decrease in the stimulatory vagal impulses to the stomach, and that it acts in the brain via receptors insensitive to @entity18229 . Brain biogenic @entity1154 , but not opioid peptides or @entity2918 seem to be involved in the central gastric antisecretory action of @entity859 .
